These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37234387)

  • 21. Efficacy and Safety of Tolvaptan in Patients More Than 90 Years Old With Acute Heart Failure.
    Sato Y; Uzui H; Mukai M; Shiomi Y; Hasegawa K; Ikeda H; Tama N; Fukuoka Y; Morishita T; Ishida K; Kaseno K; Miyazaki S; Nakano A; Tada H
    J Cardiovasc Pharmacol Ther; 2020 Jan; 25(1):47-56. PubMed ID: 31280620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial.
    Gheorghiade M; Gattis WA; O'Connor CM; Adams KF; Elkayam U; Barbagelata A; Ghali JK; Benza RL; McGrew FA; Klapholz M; Ouyang J; Orlandi C;
    JAMA; 2004 Apr; 291(16):1963-71. PubMed ID: 15113814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial.
    Gheorghiade M; Pang PS; Ambrosy AP; Lan G; Schmidt P; Filippatos G; Konstam M; Swedberg K; Cook T; Traver B; Maggioni A; Burnett J; Grinfeld L; Udelson J; Zannad F
    Heart Fail Rev; 2012 May; 17(3):485-509. PubMed ID: 21932146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Right ventricular contractility affects the clinical efficacy of add-on tolvaptan following hospitalization for heart failure in patients with significant tricuspid regurgitation.
    Hachiya R; Mochizuki Y; Shibakai M; Omomo Y; Kuroki Y; Endo Y; Ichikawa S; Miyazaki H; Chino S; Toyosaki E; Ota M; Fukuoka H; Shinke T
    Heart Vessels; 2022 May; 37(5):755-764. PubMed ID: 34677658
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF).
    Klein L; Massie BM; Leimberger JD; O'Connor CM; Piña IL; Adams KF; Califf RM; Gheorghiade M;
    Circ Heart Fail; 2008 May; 1(1):25-33. PubMed ID: 19808267
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term administration of tolvaptan ameliorates annual decline in estimated glomerular filtration rate in outpatients with chronic heart failure.
    Nakao K; Horio T; Yoshimura R; Fujiwara R; Matsuoka Y; Yokouchi G; Nakamura H; Sakamoto Y; Fujimoto K; Izumiya Y; Yoshiyama M; Kasayuki N
    Heart Vessels; 2021 Aug; 36(8):1175-1182. PubMed ID: 33580283
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety of add-on tolvaptan in patients with furosemide-resistant congestive heart failure complicated by advanced chronic kidney disease: a sub-analysis of a pharmacokinetics/ pharmacodynamics study.
    Tominaga N; Kida K; Matsumoto N; Akashi YJ; Miyake F; Kimura K; Shibagaki Y
    Clin Nephrol; 2015 Jul; 84(1):29-38. PubMed ID: 25997504
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel validated method for predicting the risk of re-hospitalization for worsening heart failure and the effectiveness of the diuretic upgrading therapy with tolvaptan.
    Takimura H; Hada T; Kawano M; Yabe T; Takimura Y; Nishio S; Nakano M; Tsukahara R; Muramatsu T
    PLoS One; 2018; 13(11):e0207481. PubMed ID: 30427915
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of renal function on mid-term outcomes in heart failure patients treated with tolvaptan.
    Fujioka K; Mizuno S; Ichise T; Matsui T; Hirase H; Yamaguchi M; Aoyama T; Yamagishi M; Fujino N; Kawashiri MA; Hayashi K
    Ther Adv Cardiovasc Dis; 2019; 13():1753944718819064. PubMed ID: 30803403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical characteristics of responders to treatment with tolvaptan in patients with acute decompensated heart failure: Importance of preserved kidney size.
    Toda H; Nakamura K; Nakahama M; Wada T; Watanabe A; Hashimoto K; Terasaka R; Tokioka K; Nishii N; Miyoshi T; Kohno K; Kawai Y; Miyaji K; Koide Y; Tachibana M; Yoshioka R; Ito H;
    J Cardiol; 2016 Feb; 67(2):177-83. PubMed ID: 26072263
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical utility of early use of tolvaptan in very elderly patients with acute decompensated heart failure.
    Niikura H; Iijima R; Anzai H; Kogame N; Fukui R; Takenaka H; Kobayashi N
    Anatol J Cardiol; 2017 Sep; 18(3):206-212. PubMed ID: 28777097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of tolvaptan vs. furosemide in older patients with heart failure : Meta-analysis of randomized controlled trials.
    Huang WL; Yang Y; Yang J; Yang J; Wang HB; Xiong XL; Zhang YF
    Herz; 2018 Jun; 43(4):338-345. PubMed ID: 28523370
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of tolvaptan in patients requiring recurrent hospitalization for heart failure.
    Ogawa H; Ajioka M; Ishii H; Okumura T; Murase Y; Osanai H; Nakasima Y; Asano H; Sakai K; Murohara T
    Nagoya J Med Sci; 2015 Aug; 77(3):355-62. PubMed ID: 26412881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Randomized pilot trial comparing tolvaptan with furosemide on renal and neurohumoral effects in acute heart failure.
    Jujo K; Saito K; Ishida I; Furuki Y; Kim A; Suzuki Y; Sekiguchi H; Yamaguchi J; Ogawa H; Hagiwara N
    ESC Heart Fail; 2016 Sep; 3(3):177-188. PubMed ID: 27818782
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of low body temperature and poor outcomes in patients admitted with worsening heart failure: a substudy of the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial.
    Payvar S; Spertus JA; Miller AB; Casscells SW; Pang PS; Zannad F; Swedberg K; Maggioni AP; Reid KJ; Gheorghiade M;
    Eur J Heart Fail; 2013 Dec; 15(12):1382-9. PubMed ID: 23858000
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-term effects and prognosis in acute heart failure treated with tolvaptan: the AVCMA trial.
    Suzuki S; Yoshihisa A; Yamaki T; Sugimoto K; Kunii H; Nakazato K; Abe Y; Saito T; Ohwada T; Suzuki H; Saitoh S; Kubota I; Takeishi Y
    Biomed Res Int; 2014; 2014():704289. PubMed ID: 25436213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictors of Poor Very Early Diuretic Response and Effectiveness of Early Tolvaptan in Symptomatic Acute Heart Failure.
    Takimura H; Kurozumi A; Taniguchi R; Tsuzuki I; Tajima E; Yamaguchi Y; Kawano M; Takimura Y; Nishio S; Nakano M; Tsukahara R
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):185-196. PubMed ID: 36739357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relationship between the time until commencement of tolvaptan and the length of hospital stay in heart failure patients.
    Kiuchi S; Hisatake S; Kabuki T; Oka T; Dobashi S; Fujii T; Ikeda T
    Heart Vessels; 2018 Apr; 33(4):367-373. PubMed ID: 29128961
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population.
    Matsue Y; Suzuki M; Seya M; Iwatsuka R; Mizukami A; Nagahori W; Ohno M; Matsumura A; Hashimoto Y
    J Cardiol; 2013 Feb; 61(2):169-74. PubMed ID: 23159210
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.